The asset management industry is expecting a wave of liquidity risk regulation. Ever since the Financial Stability Board (FSB), an advisory body of the G20, identified liquidity risk as one of the most critical ways asset management may threaten the stability of the global financial markets, regulators have been preparing guidelines and recommendations for the industry.
Meanwhile, asset managers are becoming increasingly aware that their current approach to managing liquidity risk is no longer adequate to meet today’s challenges. Recent developments have underlined the need for in-depth discussion as to how liquidity risk management can be handled effectively. We have thought about this question carefully and have come up with our own framework.
A discussion about liquidity risk management frameworks should begin with a definition as to exactly what liquidity risk is. We apply a rather unorthodox definition of liquidity risk. We differentiate between episodic liquidity risk and incremental liquidity risk. Episodic liquidity risk is the risk that it will not be possible to sell assets quickly or cost-efficiently enough to meet funding obligations. Incremental liquidity risk is the risk that subscriptions and redemptions in a fund will result in investor dilution, due to the associated transaction costs for the fund.
That side of liquidity risk is often overlooked. You might say that incremental liquidity risk is the silent assassin of fund performance and investor returns. To be considered effective, a liquidity risk management framework should prevent and mitigate episodic and incremental liquidity risk. Ex-ante liquidity risk management tools help prevent the liquidity risk from arising in the first place. If it does occur, ex-post liquidity risk management tools help mitigate its impact.
A liquidity risk management framework should also include tools to address extraordinary liquidity risk and the associated governance. The decision to use extraordinary liquidity risk management tools should not be taken lightly. Measuring, monitoring and mitigating liquidity risk are key parts of the liquidity risk management framework. In our approach, monitoring liquidity risk comes down to one formula: liquidity supply minus liquidity demand equals the liquidity surplus or shortfall.
The result of the monitoring is translated into a portfolio liquidity risk severity score that is easy to understand. Measuring and monitoring liquidity risk comprehensively does not have to increase the complexity of the procedures already in place. We believe this framework is complete and comprehensive and will be able to weather the storm of liquidity risk regulation brewing on the horizon.
This report is not available for users from countries where the offering of foreign financial services is not permitted, such as US Persons.
Your details are not shared with third parties. This information is exclusively intended for professional investors. All requests are checked.
The Robeco Capital Growth Funds have not been registered under the United States Investment Company Act of 1940, as amended, nor the United States Securities Act of 1933, as amended. None of the shares may be offered or sold, directly or indirectly in the United States or to any US Person.
This website is intended for use only by non-U.S. Persons outside of the United States (within the meaning of Regulation S promulgated under the Securities Act of 1933, as amended (the “Securities Act”)) who are professional investors. By clicking “I Agree” below and accessing the information on this website, including any subdomain thereof, you are certifying and agreeing to the following: (i) you have read, understood and agree to this disclaimer, (ii) you have informed yourself of any applicable legal restrictions and represent that by accessing the information contained on this website, you are not in violation of, and will not be causing Robeco or any of its affiliated entities or issuers to violate, any applicable laws and, as a result, you are legally authorized to access such information, (iii) you understand and acknowledge that certain information presented herein relates to securities that have not been registered under the Securities Act, and may be offered or sold only outside the United States (within the meaning of Regulation S under the Securities Act) and only to, or for the account or benefit of, non-U.S. Persons (within the meaning of Regulation S under the Securities Act), (iv) you are a non-U.S. Person (within the meaning of Regulation S under the Securities Act) located outside of the United States (within the meaning of Regulation S under the Securities Act) and (v) you are a professional non-retail investor.
Access to this website has been limited so that it shall not constitute directed selling efforts (as defined in Regulation S under the Securities Act) in the United States.
Nothing contained herein constitutes an offer to sell securities or solicitation of an offer to purchase any securities in any jurisdiction.
We reserve the right to deny access to any visitor, including, but not limited to, those visitors with IP addresses residing in the United States.This website has been carefully prepared by Robeco Institutional Asset Management B.V. (Robeco). The information contained in this publication is based upon sources of information believed to be reliable. Robeco is not answerable for the accuracy or completeness of the facts, opinions, expectations and results referred to therein. Whilst every care has been taken in the preparation of this website, we do not accept any responsibility for damage of any kind resulting from incorrect or incomplete information. This website is subject to change without notice. The value of the investments may fluctuate. Past performance is no guarantee of future results. If the currency in which the past performance is displayed differs from the currency of the country in which you reside, then you should be aware that due to exchange rate fluctuations the performance shown may increase or decrease if converted into your local currency. For investment professional use only. Not for use with the general public.